The health technology assessment agency has recommended in final draft guidance that Opdivo (nivolumab) plus Yervoy (ipilimumab) be used on the NHS in England, Wales and Northern Wales to treat adults with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) unresectable or metastatic colorectal cancer.
Approximately 44,000 people in the UK are diagnosed with colorectal cancer, also known as bowel cancer, every year. Up to 7% of patients with metastatic disease have dMMR or MSI-H tumours and, as a result, are less likely to benefit from conventional chemotherapy and typically have a poor prognosis…
